FDA approves Bristol-Myers multiple sclerosis drug

The U.S. Food and Drug Administration on Thursday approved Bristol-Myers Squibb Co’s multiple sclerosis (MS) treatment, Zeposia, one of the key treatments behind the U.S. drugmaker’s $74 billion acquisition of Celgene last year.
The company said the drug, also known as ozanimod, was approved for treating relapsing forms of MS.
Multiple sclerosis affects about 400,000 people in the United States and can be a potentially disabling disease that affects the brain and spinal cord.

Most Read

Hackers linked to Iran target WHO staff emails during coronavirus - sources

Jos Sex Video : Girl who resembles actor in Jos sex video faces hostility

Heroic nurses need full protection against coronavirus, association says

COVID-19: Hydroxychloroquine rated ‘most effective’ coronavirus treatment, poll of doctors finds

COVID-19: Athletes face mental health risks

COVID-19: Insensitivity of Nigeria's political elite

Zoom Sends Encryption Keys To China (Sometimes)

Beware of sites offering free internet plans, NCC warns Nigerians

Football will be totally different after coronavirus- Infantino

Banks bow to pressure and axe shareholder payments